Genmab — Maj 2016
-
Revlimid starter også med Tyskland og Spanien: "Global launches
Celgene expects to benefit from the launch of Revlimid as a first-line therapy for MM in the United States, Germany, and Spain. The company also expects approval in France, Italy, and Japan in 2016. The company is looking forward to strong volume demand for Revlimid in 2016. Pomalyst should also witness strong revenues in Japanese markets".
-
-
Jeg fik den i indbakken. Tak for den til rette vedkommende.
-
Spændende slutauktion.
-
Revlimid og Pomalyst når en omsætning på over 9bn USD i 2017. Det kan ikke passe Darzalex skal vente til 2025 på det!
-
Darzalex er jo de andre overlegne, og vil blive rygraden
-
Enig MUFC.
-
1205 luk -
Luk i stort set dagens højeste. Det lover godt for starten i morgen.
-
Enig.
-
vild dag - tillykke til alle
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind